Lucid Genomics: This DNA AI is a million dollar investor – on Pitchdeck

Mit Codes know the Gründer Uirá Souto Melo and Hossein Moeinzadeh aus. It is impossible to work with Quellcodes, if an app programming is less. The Forscher is interested in all possible codes, but then in the human DNA finds. If you use ACGCGTATA or TGCGGCAT, you can use the representation of the nukleine base of Adenin, Cytosin, Guanin and Thymin to obtain the properties of a certain type: Who is abroad, will produce the protein and drive out its effect. If the man is then “Gen”, the belief is everything then the “Genom”. It is likely that the DNA blurring was completed by the General-Buchstaben 3.2 million years ago.

Innerhalb von Geneen often occurs with mutations, which could develop spontaneously or spontaneously and cause severe illness to recover. One of these faster and präziser zu recognize, Uirá Souto Melo, Molekular-Genetiker, and Hossein Moeinzadeh, Computer Biologist, has an intelligent intelligence for the collected DNA analysis. They also create Quellcodes for DNA codes. Ihr Startup Lucid Genomics, founded 2024, is a spin-off of the Max-Planck Institutes for Genetics and Charity in Berlin. Let’s take a closer look at the first Million ein.

Gründer entschlüsseln from “Dunkle Genom”

With the technology of Lucid Genomics it is more complicated to identify and integrate the human DNA. Genau has the Gründer in the work of AI with the help of the Lernalgorithm training, with a Vielzahl-transformed data, variations in codieren as in non-codierenden that recognize DNA. The difference: Codierende possible variations that are described in the DNA, die for the production of proteins that are like that. There can not be made different types of variations in the activity, but the timing of the protein production is adjusted.

The Forschern is about a Durchbruch: So beschränken sich bischränken analyseverfahren de Gründern zweifolge af completely zwei Prozent des Genoms en vernachlässigen the sogenannte “Dunkle Genom” (Dark Genom) – the non-cooperative range of DNA. “The absence of the DNA and its effects on the recovery of proteins was a success in its progress, thus ensuring full function and efficiency,” says CEO Uirá Souto Melo. Allerdings where this bereiche contains a large amount of genetic materials and that which contains information, are the healthy properties of the material.

“There is no longer a vision, with a SaaS platform that offers a digital solution, that can deliver 100 percent of the DNA sequence data,” said CTO Hossein Moeinzadeh. If a tool contains data from the DNA sequences that are available, the tool becomes ‘true bad mutations’ in the DNA of patients a. My startup will focus on the creditworthiness, the medical and clinical studies that are aimed at developing research, clinical and pharmaceutical studies.

The time-tests of the Genetic Researcher of the Berliner Charité, the University Clinics of Schleswig-Holstein and the University College London that are free for startups. Artificially sollen customers in the area of diagnosis, before the platform 2025 was launched, for an analysis of the DNA probe for 150 euros. “The further price structure depends on different factors,” said Souto Melo. There are other offers in health care and pharmaceutical products that yield other prices. Market forces lead to the Gründer-Step. The technology used is based on a selective automatic, heart, knoch and netzhauter diseases. If the AI is in the credit diagnosis, further medical treatment is carried out.

1.3 million euros for Lucid Genomics

For the further development of the platform, the founder is now a fresh capital-beschafft. 1.3 million euros are raised for Lucid Genomics in the first financing round. It concerns the Munich-based risk capital fund Ceasar Ventures, after which the current Finleap manager Carolin Gabor gets the bill. Darüber was part of the early phase investor BIF Partners, Another.Vc as well as the Accelerator of the Max Planck Institutes MPF.

Rund half of the now assembled capital goods in the software development and the team designs. They start with starting such companies, medical genetics and genomics data scientists. “Concrete plans with the algorithms that we optimize, a genetic identification mutations nor prices for gestalts and the platform for the market launch,” says CEO Souto Melo.

The research into human geneticist Stefan Mundlos, with the charity and charitable organization of bioinformatician Martin Vingron, of the Max Planck Institute for Genetics and the doctor of Moeinzade ist.

Who the founders of Lucid Genomics are, is the Health-Tech investor of his DNA-AI who does his research, see here. The Pitchdeck is exclusively the founders scene. You can find more exciting presentations on the Pitchdeck-Themensite.